Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

81.61 -1.32 (-1.59%)

Delayed Quote Updated: 10:31 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 03, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

July 27, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

July 25, 2023

From Mirum Pharmaceuticals

Via Business Wire

Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know ↗

July 18, 2023

Via Benzinga

The Latest Analyst Ratings for Mirum Pharmaceuticals ↗

June 15, 2023

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

May 22, 2023

Via Benzinga

Mirum Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

July 18, 2023

B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02...

Via Benzinga

Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗

July 17, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...

Via Benzinga

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

July 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 17, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

June 23, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology

June 14, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 09, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress

June 07, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗

June 03, 2023

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...

Via Talk Markets

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

May 19, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis

May 18, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting

May 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

May 11, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 04, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

April 27, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

April 13, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 12, 2023

Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...

Via Benzinga

American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday ↗

April 12, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

April 12, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

April 12, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.